GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Piramal Pharma Ltd (NSE:PPLPHARMA) » Definitions » Net Income From Continuing Operations

Piramal Pharma (NSE:PPLPHARMA) Net Income From Continuing Operations : ₹178 Mil (TTM As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Piramal Pharma Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Piramal Pharma's net income from continuing operations for the three months ended in Mar. 2024 was ₹1,013 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was ₹178 Mil.

Piramal Pharma Net Income From Continuing Operations Historical Data

The historical data trend for Piramal Pharma's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Piramal Pharma Net Income From Continuing Operations Chart

Piramal Pharma Annual Data
Trend Mar21 Mar22 Mar23 Mar24
Net Income From Continuing Operations
3,491.10 4,410.30 -1,605.60 1,198.00

Piramal Pharma Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 501.10 -985.80 50.20 101.10 1,012.70

Piramal Pharma Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹178 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Piramal Pharma (NSE:PPLPHARMA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Piramal Pharma Ltd (NSE:PPLPHARMA) » Definitions » Net Income From Continuing Operations
Comparable Companies
BOM:533573 BOM:524816 BOM:543064 BOM:506820 BOM:540596 BOM:500126 BOM:540222 BOM:532482 BOM:524742 BOM:543322 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
543635:India
Address
Piramal Ananta, Agastya Corporate Park, Opposite Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai, MH, IND, 400070
Website
https://www.piramal.com
Piramal Pharma Ltd offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 15 global facilities and a global distribution network in over 100 countries. It includes integrated contract development and manufacturing organization business, complex hospital generics business, and India consumer healthcare business, selling over-the-counter products in India.

Piramal Pharma (NSE:PPLPHARMA) Headlines

No Headlines